undamentalytics Newsletter
Sign in

Beam Therapeutics Inc. income statement

In fiscal 2025, Beam Therapeutics Inc. reported revenue of $140m, up 120.0% on the year before, operating income of −$384m (a -274.6% margin) and net income of −$80.0m, or −$0.81 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Revenue00526137864140147
Research and development55103387312437368410409
General and administrative21305788117112114130
Operating income−75−133−392−338−176−416−384−393
Income before tax—−195−371−260−131−377−80—
Income tax00031000
Net income−78−195−371−289−133−377−80−108
Diluted EPS−$14.05−$4.19−$5.77−$4.13−$1.72−$4.58−$0.81−$1.04
Diluted shares (average)6m47m64m70m77m82m99m104m
EBITDA−72−128−385−324−156−394−361−370

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: BEAM vs KPTIAGEN vs BEAMBEAM vs IBRXBEAM vs NUVB

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Beam Therapeutics Inc.'s SEC filings (10-K and 10-Q), retrieved November 3, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Beam Therapeutics Inc.